XCT0135908

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522619

CAS#: 300837-31-4

Description: XCT0135908 is a RXR agonist. XCT0135908 showed selectivity for RXR−Nurr1 over a broad range of other RXR dimerization partners but with rather low potency. XCT0135908 yielded promising results in a rat neuron PD model. Note: Sci-Finder registered this compound as XCT 0315908.


Price and Availability

Size
Price

1g
Ask price
Size
Price

2g
Ask price
Size
Price

5g
Ask price

XCT0135908 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 522619
Name: XCT0135908
CAS#: 300837-31-4
Chemical Formula: C21H19N3O2
Exact Mass: 345.1477
Molecular Weight: 345.402
Elemental Analysis: C, 73.03; H, 5.54; N, 12.17; O, 9.26


Synonym: XCT0135908; XCT-0135908; XCT 0135908.

IUPAC/Chemical Name: 4-((5-allyl-6-methyl-2-phenylpyrimidin-4-yl)amino)benzoic acid

InChi Key: SQYRBODOBCAROZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H19N3O2/c1-3-7-18-14(2)22-19(15-8-5-4-6-9-15)24-20(18)23-17-12-10-16(11-13-17)21(25)26/h3-6,8-13H,1,7H2,2H3,(H,25,26)(H,22,23,24)

SMILES Code: O=C(O)C1=CC=C(NC2=NC(C3=CC=CC=C3)=NC(C)=C2CC=C)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1. Preparation of 4-​amino substituted condensed pyrimidine compounds as selective PDE4 inhibitors useful in treatment of diseases
By Konetzki, Ingo; Jakob, Florian; Craan, Tobias; Hesslinger, Christian
From PCT Int. Appl. (2014), WO 2014117947 A1 20140807. | Language: English, Database: CAPLUS

2. Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
By Gurney, Mark E.; Atkins, Collen M.; Adaikkalasamy, David J.; Dietrich, W. Dalton
From U.S. Pat. Appl. Publ. (2014), US 20140121221 A1 20140501. | Language: English, Database: CAPLUS

3. Treatment of neurodegenerative diseases using retinoid X receptor (RXR)​-​selective agonists
By Burstein, Ethan S.; Olsson, Roger; McFarland, Krista
From PCT Int. Appl. (2013), WO 2013020966 A1 20130214. | Language: English, Database: CAPLUS

4. Treatment of neurodegenerative diseases using retinoid X receptor (RXR)​-​selective agonists
By Burstein, Ethan S.; Olsson, Roger; McFarland, Krista
From Eur. Pat. Appl. (2013), EP 2556827 A1 20130213. | Language: English, Database: CAPLUS

5. Discovery of selective PDE4B inhibitors
By Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; et al
From Bioorganic & Medicinal Chemistry Letters (2009), 19(12), 3174-3176. | Language: English, Database: CAPLUS

6. Electrospray Mass Spectrometry for the Direct Accurate Mass Measurement of Ligands in Complex With the Retinoid X Receptor α Ligand Binding
By Lengqvist, Johan; Alvelius, Gunvor; Joernvall, Hans; Sjoevall, Jan; Perlmann, Thomas; Griffiths, William J.
From Journal of the American Society for Mass Spectrometry (2005), 16(10), 1631-1640. | Language: English, Database: CAPLUS

7. Substituted pyrimidine compositions and methods using them for the treatment of NGFI-​B-​related diseases
By Martin, Richard; Mohan, Raju; Ordentlich, Peter
From PCT Int. Appl. (2005), WO 2005047268 A2 20050526. | Language: English, Database: CAPLUS